Clinical Efficacy of Including Capecitabine in Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Li, Qiuyun ^a   Jiang, Yi ^a   Wei, Wei ^a   Yang, Huawei ^a   Liu, Jianlun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; GEMCITABINE; TAXANE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTHRACYCLINES; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MODELS, STATISTICAL; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TAXOIDS; TREATMENT OUTCOME;

EID: 84871882664     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053403     Document Type: Article

References (25)

1. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, et al. (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, et al. (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-3365.
3. Koukourakis GV, Kouloulias V, Koukourakis MJ, Zacharias GA, Zabatis H, et al. (2008) Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules 13: 1897-1922.
4. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, et al. (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019.
5. Blum JL, (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6: 56-64.
6. O'Shaughnessy J, (2002) Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 38Suppl 2: 10-14.
7. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, et al. (2003) Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14: 1227-1233.
8. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, et al. (2009) NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 7: 1060-1096.
9. Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, et al. (2004) A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 10: 6764-6769.
10. Manga GP, Shahi PK, Urena MM, Pereira RQ, Plaza MI, et al. (2010) Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer. Breast Cancer 17: 205-211.
11. Jinno H, Sakata M, Hayashida T, Takahashi M, Mukai M, et al. (2010) A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. Ann Oncol 21: 1262-1266.
12. Perez-Manga G, Mendez M, Palomero MI, et al. (2005) Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin(A) and capecitabine (X) in locally advanced or inflammatory breast cancer. EJC Suppl: 133.
13. Lybaert W, Wildiers H, Neven P, et al. (2005) Neoadjuvant capecitabine (X) plus docetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data. EJC Suppl: 105.
14. von MG, Rezai M, Loibl S, Fasching PA, Huober J, et al. (2010) Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28: 2015-2023.
15. Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, et al. (2012) Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat 132: 843-851.
16. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, et al. (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366: 310-320.
17. Lee KS, Ro J, Nam BH, Lee ES, Kwon Y, et al. (2008) A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 109: 481-489.
18. Steger GG, Greil R, Jakesz R, Lang A, Mlineritsch B, et al. (2010) Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). J Clin Oncol. June: abstr 530.
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 17: 1-12.
20. Kuritz SJ, Landis JR, Koch GG, (1988) A general overview of Mantel-Haenszel methods: applications and recent developments. Annu Rev Public Health 9: 123-160.
21. DerSimonian R, Kacker R, (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28: 105-114.
22. Egger M, Davey SG, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
23. Villman K, Ohd JF, Lidbrink E, Malmberg L, Lindh B, et al. (2007) A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer 43: 1153-1160.
24. Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, et al. (2009) Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. Eur J Surg Oncol 35: 1048-1054.
25. Lu YS, Chen DR, Tseng LM, Yeh DC, Chen ST, et al. (2011) Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. Cancer Chemother Pharmacol 67: 1257-1263.